Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Filgrastim (Filgrastim/SBS) 300 mcg SC injection relative to Filgrastim (Filgrastim/CIM) 300 mcg SC injection

Trial Profile

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Filgrastim (Filgrastim/SBS) 300 mcg SC injection relative to Filgrastim (Filgrastim/CIM) 300 mcg SC injection

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Feb 2019

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Neutropenia
  • Focus Pharmacokinetics
  • Sponsors Siam Bioscience
  • Most Recent Events

    • 15 Jan 2019 Status changed from recruiting to completed.
    • 11 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 18 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top